Status:
COMPLETED
Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients With Psoriasis
Lead Sponsor:
National and Kapodistrian University of Athens
Collaborating Sponsors:
Andreas Syggros Hospital of Venereal and Dermatological Diseases
Conditions:
Psoriasis
Cardiovascular Disease
Eligibility:
All Genders
18+ years
Brief Summary
Data on the antiatherogenic effect of IL23 inhibitors are sparse. This study aimed to assess the impact of one-year treatment with an IL17 or IL23 inhibitor on arterial stiffness in patients with mode...
Eligibility Criteria
Inclusion
- Moderate-to-severe psoriasis (Psoriasis Area Severity Index (PASI) score \> 10 or Body Surface Area (BSA) \>10 or Dermatology Life Quality Index (DLQI) \>10)
- Indication for treatment with an IL17 or an IL23 inhibitor based on disease characteristics and comorbidities
Exclusion
- Prior treatment with an IL17 or an IL23 inhibitor
- Prior therapy with an TNFa-inhibitor for up to 3 months before entering the study
- Chronic or severe acute infections, malignancy
- Pregnancy or lactation
Key Trial Info
Start Date :
September 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2024
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT07169682
Start Date
September 1 2021
End Date
September 30 2024
Last Update
September 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Andreas Sygros Hospital
Athens, Greece, 17124